Advanced search
Publication Cover
Therapeutics and Clinical Risk Management Volume 14, 2018 - Issue
Submit an article Journal homepage
64
Views
12
CrossRef citations to date
0
Altmetric
Review

Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab

Todd Wechter1 Stony Brook Medicine, Stony Brook, NY, USA, [email protected]Correspondence[email protected]
,
Abigail Cline2 Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA
&
Steven R Feldman2 Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA;3 Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA;4 Department of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA
Pages 1489-1497 | Published online: 22 Aug 2018

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Giulia Coscarella, Dalma Malvaso, Maria Mannino, Giacomo Caldarola, Barbara Fossati, Clara De Simone, Andrea Chiricozzi & Ketty Peris. (2023) The preclinical discovery and development of deucravacitinib for the treatment of psoriasis. Expert Opinion on Drug Discovery 18:11, pages 1201-1208.
Read now
Maria Sole Chimenti, Paola Triggianese, Erica De Martino, Paola Conigliaro, Giulia Lavinia Fonti, Flavia Sunzini, Francesco Caso, Carlo Perricone, Luisa Costa & Roberto Perricone. (2019) An update on pathogenesis of psoriatic arthritis and potential therapeutic targets. Expert Review of Clinical Immunology 15:8, pages 823-836.
Read now
Lluís Puig. (2019) Guselkumab for the treatment of adults with moderate to severe plaque psoriasis. Expert Review of Clinical Immunology 15:6, pages 589-597.
Read now

Articles from other publishers (9)

M. Nogueira, R.B. Warren & T. Torres. (2020) Risk of tuberculosis reactivation with interleukin (IL)‐17 and IL‐23 inhibitors in psoriasis – time for a paradigm change. Journal of the European Academy of Dermatology and Venereology 35:4, pages 824-834.
Crossref
Alan Menter, Gerald G. Krueger, So Yeon Paek, Dario Kivelevitch, Iannis E. Adamopoulos & Richard G. Langley. (2021) Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities. Dermatology and Therapy 11:2, pages 385-400.
Crossref
Joshua S. Davis, David Ferreira, Emma Paige, Craig Gedye & Michael Boyle. (2020) Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. Clinical Microbiology Reviews 33:3.
Crossref
V. V. Chikin. (2020) Guselkumab in the treatment of patients with plaque psoriasis of moderate and severe severity: Efficacy and safety of interleukin-23 blockade. Vestnik dermatologii i venerologii 95:6, pages 68-77.
Crossref
Giovanni Damiani, Alessia Pacifico, Dennis M. Linder, Paolo D.M. Pigatto, Rosalynn Conic, Ayman Grada & Nicola L. Bragazzi. (2019) Nanodermatology‐based solutions for psoriasis: State‐of‐the art and future prospects. Dermatologic Therapy 32:6.
Crossref
Birgit Reyn, Ann Gils & Tom Hillary. (2019) Eczematous eruption after guselkumab treatment for psoriasis. JAAD Case Reports 5:11, pages 973-975.
Crossref
Janet Fricker. (2019) IL-23 Inhibition as a Key Component in Psoriasis Treatment is Here to Stay. EMJ Dermatology, pages 2-11.
Crossref
Janet Fricker. (2019) IL-23 Inhibition as a Key Component in Psoriasis Treatment is Here to Stay. EMJ Dermatology, pages 2-11.
Crossref
K. Reich, K.A. Papp, A.W. Armstrong, Y. WasfiS. LiY.K. ShenB. RandazzoM. SongA.B. Kimball. (2019) Safety of guselkumab in patients with moderate‐to‐severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies . British Journal of Dermatology 180:5, pages 1039-1049.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.